UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

Clinical pharmacokinetics, 2009, Vol.48 (1), p.1-22

2009

Volltextzugriff (PDF)

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

European journal of pharmaceutical sciences, 2021-02, Vol.157, p.105631-105631, Article 105631

2021

Volltextzugriff (PDF)

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Chest, 2012-02, Vol.141 (2 Suppl), p.e44S-e88S

2012

Volltextzugriff (PDF)

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Neuropharmacology, 2018-09, Vol.140, p.107-120

2018

Volltextzugriff (PDF)

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Journal of clinical oncology, 2019-03, Vol.37 (9), p.741-750

2019

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical pharmacokinetics, 2014-01, Vol.53 (1), p.1-16

2014

Volltextzugriff (PDF)

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis

Circulation (New York, N.Y.), 2015-03, Vol.131 (11), p.972-979

2015

Volltextzugriff (PDF)

5‑(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Journal of medicinal chemistry, 2017-09, Vol.60 (17), p.7524-7538

2017

Volltextzugriff (PDF)

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients

American journal of kidney diseases, 2015-07, Vol.66 (1), p.91-98

2015

Volltextzugriff (PDF)

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.455-466

2013

Volltextzugriff (PDF)

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Annals of oncology, 2017-03, Vol.28 (3), p.512-518

2017

Volltextzugriff (PDF)

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer

Journal of controlled release, 2018-12, Vol.291, p.184-195

2018

Volltextzugriff (PDF)

PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

Arteriosclerosis, thrombosis, and vascular biology, 2018-02, Vol.38 (2), p.448-456

2018

Volltextzugriff (PDF)

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.317-328

2012

Volltextzugriff (PDF)

Rivaroxaban: Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention

Clinical pharmacokinetics, 2011-10, Vol.50 (10), p.675-686

2011

Volltextzugriff (PDF)

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2013-07, Vol.76 (1), p.89-98

2013

Volltextzugriff (PDF)

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)‑N‑((S)‑3-(Cyclopent-1-en-1-yl)-1-((R)‑2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)‑2-(2-morpholinoacetamido)propanamido)propenamide)

Journal of medicinal chemistry, 2018-12, Vol.61 (24), p.11127-11143

2018

Volltextzugriff (PDF)

Simultaneous quantification of baloxavir marboxil and its active metabolite in human plasma using UHPLC-MS/MS: Application to a human pharmacokinetic study with different anticoagulants

Journal of pharmaceutical and biomedical analysis, 2024-10, Vol.249, p.116387, Article 116387

2024

Volltextzugriff (PDF)

Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo

Antiviral research, 2024-07, Vol.227, p.105890, Article 105890

2024

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4‑d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Journal of medicinal chemistry, 2016-09, Vol.59 (17), p.8103-8124

2016

Volltextzugriff (PDF)

Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses

Journal of medicinal chemistry, 2020-09, Vol.63 (17), p.9403-9420

2020

Volltextzugriff (PDF)

Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban

Canadian journal of cardiology, 2013-07, Vol.29 (7), p.S24-S33

2013

Volltextzugriff (PDF)

The effect of food on the absorption and pharmacokinetics of rivaroxaban

International journal of clinical pharmacology and therapeutics, 2013-07, Vol.51 (7), p.549-561

2013

Volltextzugriff (PDF)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2010-11, Vol.70 (5), p.703-712

2010

Volltextzugriff (PDF)

1 – 25 von 888

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(826)
Mit Volltextzugriff
(685)

Publikationsform

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(747)
Life Sciences & Biomedicine
(730)
Humans
(602)
Morpholines - Pharmacokinetics
(600)
Animals
(438)
Male
(428)
Pharmacology & Pharmacy
(412)
Morpholines - Pharmacology
(331)
Biological And Medical Sciences
(277)
Female
(263)
Medical Sciences
(259)
Morpholines - Administration & Dosage
(245)
Pharmacology. Drug Treatments
(219)
Rats
(203)
Adult
(193)
Administration, Oral
(186)
Pharmacokinetics
(186)
Morpholines - Therapeutic Use
(155)
Rivaroxaban
(154)
Dose-Response Relationship, Drug
(151)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis

5‑(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Dose-Finding Study of Rivaroxaban in Hemodialysis Patients

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer

PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Rivaroxaban: Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)‑N‑((S)‑3-(Cyclopent-1-en-1-yl)-1-((R)‑2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)‑2-(2-morpholinoacetamido)propanamido)propenamide)

Simultaneous quantification of baloxavir marboxil and its active metabolite in human plasma using UHPLC-MS/MS: Application to a human pharmacokinetic study with different anticoagulants

Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4‑d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses

Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban

The effect of food on the absorption and pharmacokinetics of rivaroxaban

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Suchergebnisse filtern